Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Stadler

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Investigational New Drugs|July 9, 2002
New trial designs to assess antitumor and antiproliferative agents in prostate cancerWalter Stadler
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: randomized discontinuation trial designWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|September 20, 2006
New therapeutic options for renal cell carcinomaWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|May 17, 2022
Emerging targets in kidney cancer: opportunities for drug developmentWalter Stadler
Urologic Oncology|March 14, 2007
Fuzzy thinking on biomarkersWalter Stadler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug developmentWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|July 26, 2008
Angiogenesis inhibition in non-clear cell renal cancerWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Developing drugs that do not cause tumor regressionWalter Stadler
Current Opinion in Oncology|September 22, 2006
SorafenibOlwen Hahn, Walter Stadler
Critical Reviews in Oncology/Hematology|July 10, 2003
Angiogenesis inhibitors in genitourinary cancersWalter Stadler, George Wilding
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Investigational New Drugs|July 9, 2002
New trial designs to assess antitumor and antiproliferative agents in prostate cancerWalter Stadler
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: randomized discontinuation trial designWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|September 20, 2006
New therapeutic options for renal cell carcinomaWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|May 17, 2022
Emerging targets in kidney cancer: opportunities for drug developmentWalter Stadler
Urologic Oncology|March 14, 2007
Fuzzy thinking on biomarkersWalter Stadler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug developmentWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|July 26, 2008
Angiogenesis inhibition in non-clear cell renal cancerWalter Stadler
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Developing drugs that do not cause tumor regressionWalter Stadler
Current Opinion in Oncology|September 22, 2006
SorafenibOlwen Hahn, Walter Stadler
Critical Reviews in Oncology/Hematology|July 10, 2003
Angiogenesis inhibitors in genitourinary cancersWalter Stadler, George Wilding
Pageof 4